The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4),
increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight
loss and lowering cardiovascular risk. A retrospective longitudinal study by Rizzo et al.
showed that DPP-4 inhibitors administration could have protective effects against cognitive
decline in diabetic elderly. Is has been observed that GLP-1 affects brain metabolism,
increases neuritic growth, and protects neuronal cells from oxidative stress and death.